Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.
Int J Oncol. 2017 Jun;50(6):1921-1933. doi: 10.3892/ijo.2017.3981. Epub 2017 May 3.
Gastric cancer (GC) is one of the most common cancers and the second leading cause of cancer-related mortality. Increasing discoveries have highlighted aberrant epigetic modifications actively contribute to the pathogenesis of this fatal disease. Among these epigenetic events, dysregulated methylation is particularly associated with GC progression. Importantly, these aberrant methylation modifications caused by the misregulation of methyltranferases are frequently reversible, which provides opportunities for targeted treatment using specific molecular inhibitors. In the present review, we provide an overview of the current literature on the changes of DNA and histone methylations that alter gene expressions in GC and describe the emerging targeted epigenetic therapy in GC.
胃癌（GC）是最常见的癌症之一，也是癌症相关死亡的第二大主要原因。越来越多的发现强调了异常的表观遗传修饰积极促进了这种致命疾病的发病机制。在这些表观遗传事件中，失调的甲基化与 GC 的进展特别相关。重要的是，由甲基转移酶的失调引起的这些异常甲基化修饰通常是可逆的，这为使用特定的分子抑制剂进行靶向治疗提供了机会。在本综述中，我们概述了目前关于改变 GC 中基因表达的 DNA 和组蛋白甲基化变化的文献，并描述了 GC 中新兴的靶向表观遗传治疗。
